NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/04/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization72.83 mln
Float407 mln
Earnings Date05/11/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-1.53
Likely manipulated
1-Year Forecast
3.75
Transformational upside
Relative Strength
1
/ 100
Severely lagging
Debt / Equity
-1.88
Negative equity
ROE
-1,566
Deeply negative
Business Description
Sangamo Therapeutics is a California-based medical research company working to develop treatments for serious genetic diseases. Its most advanced programs include gene therapies for Fabry disease and hemophilia A, as well as a cell-based therapy aimed at helping patients tolerate kidney transplants. The company also has earlier-stage research underway for conditions such as Huntington's disease and ALS. Sangamo works alongside several major pharmaceutical companies, including Pfizer, Sanofi, and Biogen, to help bring these treatments to patients.
